364 related articles for article (PubMed ID: 33467756)
1. Future Directions in the Treatment of Osteosarcoma.
Smrke A; Anderson PM; Gulia A; Gennatas S; Huang PH; Jones RL
Cells; 2021 Jan; 10(1):. PubMed ID: 33467756
[TBL] [Abstract][Full Text] [Related]
2. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
3. [Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
Orthopade; 2013 Dec; 42(12):1072. PubMed ID: 24482827
[No Abstract] [Full Text] [Related]
4. Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.
Maki RG
J Clin Oncol; 2012 Jun; 30(17):2033-5. PubMed ID: 22565001
[No Abstract] [Full Text] [Related]
5. Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
Berend KR; Pietrobon R; Moore JO; Dibernardo L; Harrelson JM; Scully SP
J Surg Oncol; 2001 Nov; 78(3):162-70. PubMed ID: 11745799
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
7. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
9. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients.
Klangjorhor J; Phanphaisarn A; Teeyakasem P; Chaiyawat P; Phinyo P; Settakorn J; Theera-Umpon N; Pruksakorn D
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1165-1176. PubMed ID: 32476109
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
13. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
14. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
15. An update on chemotherapy for osteosarcoma.
Ferrari S; Serra M
Expert Opin Pharmacother; 2015; 16(18):2727-36. PubMed ID: 26512909
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
[TBL] [Abstract][Full Text] [Related]
18. Osteosarcoma of the limb: an institutional report of 10 years experience with neoadjuvant chemotherapy and delayed surgery.
Postma A; Kamps WA; Schraffordt Koops H; Veth RP; Göeken LN; Molenaar WM
Cancer Treat Res; 1993; 62():361-4. PubMed ID: 7682095
[No Abstract] [Full Text] [Related]
19. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]